

# NUEDEXTA®

(dextromethorphan HBr and quinidine sulfate) capsules 20 mg  
10 mg

## The Importance of Screening for PBA: Dr. Fisher

**Onscreen text:** © 2023 Otsuka America Pharmaceutical, Inc. All rights reserved.

October 2023 18US23EUP0073

**Dr. Fisher:** So we were involved in a regional STAR trial, and you know the amount of patients who were identified as having the symptoms were more than I expected. I was always aware of PBA. I work with the person who talked about PBA and was one of the leaders in the field, and I was certain that I was asking the right questions and identifying them. And then the PRISM came, and the numbers that I had in my registry were so different from the PRISM registry. That's when I decided to screen everyone. We screened about 1,800 patients and I realized that being aware, asking questions, believing in the problem, I still missed 80% of the patients. At that point I decided that I would screen every patient that comes to a clinic.

**End Slate:** Otsuka America Pharmaceutical, Inc.

**Onscreen text:** Stanley Fisher, MD, was a paid consultant for their participation.

© 2023 Otsuka America Pharmaceutical, Inc. All rights reserved. October 2023 18US23EUP0073

## INDICATION and IMPORTANT SAFETY INFORMATION for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate)

### INDICATION:

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA).

PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurologic disease or injury.

### IMPORTANT SAFETY INFORMATION:

#### CONTRAINDICATIONS:

- Quinidine and Related Drugs:** NUEDEXTA contains quinidine and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine.
- Hypersensitivity:** NUEDEXTA is contraindicated in patients with a history of NUEDEXTA-, quinine-, mefloquine-, or quinidine-induced thrombocytopenia, hepatitis, bone-marrow depression, lupus-like syndrome, or known hypersensitivity to dextromethorphan (e.g., rash, hives).
- MAOIs:** NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), or in patients who have taken MAOIs within the preceding 14 days, due to the risk of serious and possibly fatal drug interactions, including serotonin syndrome. Allow at least 14 days after stopping NUEDEXTA before starting an MAOI.



Otsuka

Otsuka America Pharmaceutical, Inc.

# NUEDEXTA®

(dextromethorphan HBr and quinidine sulfate) capsules 20 mg  
10 mg

- Cardiovascular:** NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, heart failure, patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide), patients with complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block.

**Thrombocytopenia and Other Hypersensitivity Reactions:** Quinidine can cause immune-mediated thrombocytopenia that can be severe or fatal. Non-specific symptoms, such as lightheadedness, chills, fever, nausea, and vomiting, can precede or occur with thrombocytopenia. NUEDEXTA should be discontinued immediately if thrombocytopenia occurs.

**Hepatotoxicity:** Hepatitis, including granulomatous hepatitis, has been reported in patients receiving quinidine, generally during the first few weeks of therapy. Discontinue immediately if this occurs.

**Cardiac Effects:** NUEDEXTA causes dose-dependent QTc prolongation. QT prolongation can cause torsades de pointes-type ventricular tachycardia, with the risk increasing as the degree of prolongation increases. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3 to 4 hours after the first dose. Some risk factors include use with CYP3A4 inhibitors or drugs that prolong QT interval, electrolyte abnormalities, bradycardia, or left ventricular hypertrophy or dysfunction. If patients taking NUEDEXTA experience symptoms that could indicate the occurrence of cardiac arrhythmias (e.g., syncope or palpitations), NUEDEXTA should be discontinued, and the patient further evaluated.

**Concomitant Use of CYP2D6 Substrates:** NUEDEXTA inhibits CYP2D6 and may interact with other drugs metabolized by CYP2D6. Adjust dose of CYP2D6 substrates as needed.

**Dizziness:** NUEDEXTA may cause dizziness. Take precautions to reduce the risk of falls.

**Serotonin Syndrome:** Use of NUEDEXTA with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants increases the risk of "serotonin syndrome."

**Anticholinergic Effects of Quinidine:** Monitor for worsening in myasthenia gravis.

**Adverse Reactions:** The most common adverse reactions (incidence of ≥3% and two-fold greater than placebo) in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence.

These are not all the risks for use of NUEDEXTA.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 ([www.fda.gov/medwatch](http://www.fda.gov/medwatch)).

Please see **FULL PRESCRIBING INFORMATION**.



Otsuka

Otsuka America Pharmaceutical, Inc.